Overview

Efficacy and Safety of MW031 in PMO Subjects

Status:
Completed

Trial end date:
2021-09-27

Target enrollment:

Participant gender:

Summary

This study is a multicenter, randomized, double-blinded, placebo-controlled Phase III clinical study to evaluate the clinical efficacy and safety of MW031 in Chinese postmenopausal osteoporotic subjects with increased bone fracture risk .

Phase:

Phase 3

Details

Lead Sponsor:

Mabwell (Shanghai) Bioscience Co., Ltd.